The goal of the Katzen Cancer Research Center is to attract outstanding scientists to contribute to the George Washington University (GW) cancer research efforts. With the dedication of the new, state-of-the-art clinical facilities, funded by the donation, the Center is poised to considerably expand its research efforts by adding scientists, clinicians and support staff dedicated to the detection and treatment of patients with cancer, blood disorders and bone marrow disease.
Katzen Funded Research
Blocking HCV Infection-Associated Hepatocellular Carcinoma with LNA-antagomiR in Mouse Model (2nd Year Continuation)
The study focuses on activities of oncogenes including miRNAs whose activities appear to promote HCC in the HCV infected liver.
Concurrent Imaging and Treatment of Epithelial Cancers using Optical Coherence Tomography and Cold Plasmas: Imaging and Treatment of Excised Oral Cavity Tumors (2nd Year Continuation)
This proposal is a request for an additional stage of funding for our previously funded Katzen project to develop a cancer imaging and treatment probe that integrates optical coherence tomography (OCT) for imaging and cold plasmas for selective plasma treatment.
This research proposes to develop a novel microfluidics chip that will allow for single cell multiplexed characterization of a mixed population of cancer stem cells obtained by FACS (Fluorescence-activated cell sorting).
This proposal aims to define the genetic and expression background accompanying BRCA1 and BRCA2 pathogenic mutations in individuals who have not developed an early onset cancer, in comparison with mutation carriers with an early onset disease.
Development of Innovative Nano Dual Drug/Gene Delivery and Biometric 3D Printed Bone Model Platforms for Metastatic Breast Cancer Treatment and Analysis (Synergy)
This proposal aims to design a very novel delivery system involving rosette nanotubes (self-assembling guanine-cytosine dimers) covalently linked to a microRNA to target breast cancer cells, and within the nanotube will be a cytotoxic drug such as paclitaxel or tamoxifen.
Exploring Current Cancer Screening Rate and Testing Technological Solutions for Increase Adherence to Cancer Screening guidelines in the GW Community (Synergy)
Objective is to conduct formative work to assess rates and patterns of cancer screening to inform the development and feasibility of communication technologies to assist cancer care teams. The goal is to increase provider awareness of cancer screening guidelines, 2) increase cancer screenings, and 3) promote care coordination.
Prognostic Markers in Early Stage Lung Cancer: Computer Algorithms and Bayesian Regression (Clinical/Transitional)
The goal of this proposal is to build a computer algorithm to aid making reliable prognostics in early stage lung cancer. Lung cancer is typically detected at late stages ad TNM stage III or IV often associated with poor prognosis.
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). Proposed studies may help define new molecular biomarkers of HCV-infection associated liver cancer.
The currently accepted stepwise model of breast tumorigenesis assumes a gradual transition from epithelial hyperproliferation (including ADH) to ductal carcinoma in situ(DCIS) and then to invasive ductal carcinoma (IDC). This progression model is strongly supported by clinical and epidemiological data and by molecular clonally studies.
Glioblastoma is a highly malignant primary central nervous system neoplasm associated with poor survival and is invariably fatal. Recurrence in glioblastoma typically occurs locally, prompting the development of treatment that provides post-operative intracavitary delivery.
With its affiliation to George Washington University School of Medicine, the Katzen Cancer Research Center has access to physicians who wear multiple hats – as clinicians, researchers...
The Center currently sponsors clinical trials designed to advance scientific knowledge for a variety of cancers. We encourage patients to participate in our trials.